Literature DB >> 9549814

Statistical analysis of quality of life with missing data in cancer clinical trials.

A B Troxel1, D L Fairclough, D Curran, E A Hahn.   

Abstract

We summarize issues that arise when considering quality of life (QOL) data in cancer clinical trials, especially those related to missing data. We describe different types of missing data mechanisms, and discuss ways of assessing and testing missing data mechanisms. A section on presentation of study design and results describes how graphical displays can effectively document the extent of the missing data problem, as well as describe its impact on interpretation of results. Finally, we describe several different statistical methods used to analyse repeated measures, with an emphasis on their properties and their ability to adequately handle different types of missing data mechanisms. We make recommendations as to the most appropriate methods, and suggest important directions for future research.

Entities:  

Mesh:

Year:  1998        PMID: 9549814     DOI: 10.1002/(sici)1097-0258(19980315/15)17:5/7<653::aid-sim812>3.0.co;2-m

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  31 in total

1.  Missing data methods for dealing with missing items in quality of life questionnaires. A comparison by simulation of personal mean score, full information maximum likelihood, multiple imputation, and hot deck techniques applied to the SF-36 in the French 2003 decennial health survey.

Authors:  Hugo Peyre; Alain Leplège; Joël Coste
Journal:  Qual Life Res       Date:  2010-10-01       Impact factor: 4.147

2.  Reporting on quality of life in randomised controlled trials in gastrointestinal surgery.

Authors:  Valerie Bridoux; Grégoire Moutel; Benoit Lefebure; Michel Scotte; Francis Michot; Christian Herve; Jean-Jacques Tuech
Journal:  J Gastrointest Surg       Date:  2009-10-14       Impact factor: 3.452

3.  Can electronic web-based technology improve quality of life data collection? Analysis of Radiation Therapy Oncology Group 0828.

Authors:  Benjamin Movsas; Daniel Hunt; Deborah Watkins-Bruner; W Robert Lee; Heather Tharpe; Desiree Goldstein; Joan Moore; Ian S Dayes; Sara Parise; Howard Sandler
Journal:  Pract Radiat Oncol       Date:  2013-09-16

4.  Estimation of regression models for the mean of repeated outcomes under nonignorable nonmonotone nonresponse.

Authors:  Stijn Vansteelandt; Andrea Rotnitzky; James Robins
Journal:  Biometrika       Date:  2007-12       Impact factor: 2.445

5.  Acupuncture and the relaxation response for treating gastrointestinal symptoms in HIV patients on highly active antiretroviral therapy.

Authors:  Bei-Hung Chang; Elizabeth Sommers
Journal:  Acupunct Med       Date:  2011-06-24       Impact factor: 2.267

6.  Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer.

Authors:  Carol M Moinpour; Gary W Donaldson; Astra M Liepa; Allen S Melemed; Joyce O'Shaughnessy; Kathy S Albain
Journal:  Qual Life Res       Date:  2011-09-16       Impact factor: 4.147

7.  PROMIS measures of pain, fatigue, negative affect, physical function, and social function demonstrated clinical validity across a range of chronic conditions.

Authors:  Karon F Cook; Sally E Jensen; Benjamin D Schalet; Jennifer L Beaumont; Dagmar Amtmann; Susan Czajkowski; Darren A Dewalt; James F Fries; Paul A Pilkonis; Bryce B Reeve; Arthur A Stone; Kevin P Weinfurt; David Cella
Journal:  J Clin Epidemiol       Date:  2016-03-04       Impact factor: 6.437

8.  Evaluation of quality of life in a clinical trial with nonrandom dropout: the effect of epoetin alfa in anemic cancer patients.

Authors:  D L Fairclough; D D Gagnon; M J Zagari; N Marschner; M Dicato
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

9.  Validity of PROMIS physical function measured in diverse clinical samples.

Authors:  Benjamin D Schalet; Ron D Hays; Sally E Jensen; Jennifer L Beaumont; James F Fries; David Cella
Journal:  J Clin Epidemiol       Date:  2016-03-09       Impact factor: 6.437

10.  Quality of life as a clinical trial endpoint: determining the appropriate interval for repeated assessments in patients with advanced lung cancer.

Authors:  Patricia J Hollen; Richard J Gralla; Cynthia N Rittenberg
Journal:  Support Care Cancer       Date:  2004-11       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.